AbbVie Inc. disappointed investors this weekend with the presentation of Phase Ia/Ib trial for a small cell lung cancer treatment. While the data showed some encouraging results in a subset of patients with high delta-like protein-3 (DLL3) expression, overall data was not as robust as investors hoped.
The company's stock dropped more than 5% in early-morning trading, but rebounded slightly to end the day down
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?